Aadi Bioscience Past Earnings Performance
Past criteria checks 0/6
Aadi Bioscience's earnings have been declining at an average annual rate of -27.1%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 28% per year.
Key information
-27.1%
Earnings growth rate
12.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 28.0% |
| Return on equity | -62.5% |
| Net Margin | -270.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Aadi Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 24 | -66 | 45 | 0 |
| 30 Sep 23 | 23 | -63 | 45 | 0 |
| 30 Jun 23 | 22 | -62 | 44 | 9 |
| 31 Mar 23 | 19 | -62 | 42 | 0 |
| 31 Dec 22 | 15 | -61 | 40 | 0 |
| 30 Sep 22 | 11 | -63 | 39 | 0 |
| 30 Jun 22 | 7 | -136 | 36 | 13 |
| 31 Mar 22 | 3 | -119 | 27 | 0 |
| 31 Dec 21 | 1 | -111 | 19 | 0 |
| 30 Sep 21 | 14 | -87 | 9 | 0 |
| 30 Jun 21 | 15 | -2 | 2 | 0 |
| 31 Mar 21 | 15 | -6 | 2 | 0 |
| 31 Dec 20 | 15 | -4 | 2 | 0 |
| 31 Dec 19 | 1 | -13 | 2 | 0 |
Quality Earnings: 3350 is currently unprofitable.
Growing Profit Margin: 3350 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3350 is unprofitable, and losses have increased over the past 5 years at a rate of 27.1% per year.
Accelerating Growth: Unable to compare 3350's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3350 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 3350 has a negative Return on Equity (-62.52%), as it is currently unprofitable.